Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 1/20 | 0.32 |
| ▸ | ACVRL1 | P37023 | 1/20 | 0.32 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | CCNC | P24863 | 1/20 | 0.31 |
| ▸ | CDK8 | P49336 | 1/20 | 0.31 |
| ▸ | HASPIN | Q8TF76 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.31 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
| ▸ | PIM1 | P11309 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4018524 | 0.68 | APP (0.34) | — | |
| SCHEMBL13162006 | 0.68 | SIRT3 (0.51) | TGFBR1ACVRL1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL4013344 | 0.64 | MAPT (0.39) | TGFBR1ACVRL1MAPTEGLN1 | |
| SCHEMBL13162032 | 0.61 | KMT2A (0.52) | SMN1; SMN2PIM1 | |
| SCHEMBL4017932 | 0.60 | CYP1B1 (0.34) | ALDH1A1 | |
| SCHEMBL5904267 | 0.60 | ALDH1A1 (0.54) | TGFBR1ACVRL1MAPTALDH1A1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL5904437 | 0.59 | ALDH1A1 (0.53) | TGFBR1ACVRL1MAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL13634518 | 0.57 | SIRT3 (0.50) | CCNCCDK8HASPINPIM1 | |
| SCHEMBL13986993 | 0.56 | GSK3B (0.64) | MAPT | |
| SCHEMBL13162035 | 0.56 | SIRT3 (0.53) | TGFBR1ACVRL1MAPTALDH1A1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7632851-B2 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | NOVARTIS AG (CH) | 2009-12-15 | — | — | US | disclosed |
| EP-1613610-B1 | BENZO 1,2,5 OXADIAZOLES AND BENZO 1,2,5 THIADIAZOLES USEFUL AS HISTOPATHOLOGICAL STAINING AGENTS, IMAGING AGENTS AND BIOMARKERS | NOVARTIS AG (CH) | 2009-07-01 | — | — | EP | disclosed |
| US-20060093551-A1 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | NOVARTIS AG (CH) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060093551-A1 | Benzo[1,2,5]oxadiazoles and benzol[1,2,5]thiadiazoles useful as histopathological staining agents, imaging agents and biomarkers | H1-3, MKI67, H1-5 | TGFBR1 2661/4885ACVRL1 1873/4885MAPT 2136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.